Abrogation of KLF5 sensitizes <italic>BRCA1</italic>-proficient pancreatic cancer to PARP inhibition
Olaparib
PARP inhibitor
Synthetic Lethality
DOI:
10.3724/abbs.2023288
Publication Date:
2023-12-27T06:40:48Z
AUTHORS (8)
ABSTRACT
Poly ADP-ribose polymerase (PARP) inhibitor monotherapies are selectively effective in patients with pancreatic, breast, prostate, and ovarian cancers
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....